Ryder System, Inc. (R)
| Market Cap | 9.25B +60.9% |
| Revenue (ttm) | 12.66B -0.1% |
| Net Income | 491.00M -1.6% |
| EPS | 12.05 +4.9% |
| Shares Out | 38.69M |
| PE Ratio | 19.77 |
| Forward PE | 15.78 |
| Dividend | $3.64 (1.52%) |
| Ex-Dividend Date | May 18, 2026 |
| Volume | 225,428 |
| Open | 243.67 |
| Previous Close | 241.82 |
| Day's Range | 238.20 - 244.05 |
| 52-Week Range | 142.39 - 259.00 |
| Beta | 1.03 |
| Analysts | Buy |
| Price Target | 238.56 (-0.24%) |
| Earnings Date | Apr 23, 2026 |
About R
Ryder System, Inc. operates as a logistics and transportation company worldwide. It operates through three segments: Fleet Management Solutions (FMS), Supply Chain Solutions (SCS), and Dedicated Transportation Solutions (DTS). The FMS segment offers full-service leasing and leasing with flexible maintenance options; commercial vehicle rental; maintenance services; digital and technology support services; fuel services; and fuel planning and tax reporting, cards, and monitoring services, and centralized billing, as well as sells used vehicles th... [Read more]
Financial Performance
In 2025, Ryder System's revenue was $12.67 billion, an increase of 0.23% compared to the previous year's $12.64 billion. Earnings were $496.00 million, an increase of 2.06%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for R stock is "Buy." The 12-month stock price target is $238.56, which is a decrease of -0.24% from the latest price.
News
Theralase(R) Announces $4 Million Brokered LIFE Offering
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - Theralase® Technologies Inc. (TSXV: TLT...
Ryder CEO to Address Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference
MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R) Chief Executive Officer John Diez will present a company update at the 2026 Bank of America Securities Industrials, Transportati...
Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update
Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the res...
Gelum Shares Approved for Trading on the OTCQB(R) Venture Market
Vancouver, British Columbia--(Newsfile Corp. - May 4, 2026) - Gelum Resources Ltd. (CSE: GMR) (OTCQB: GMRCF) ("Gelum" or the "Company") reports that the Company's common shares have been re-approved a...
AminoQuest Labs(R) Launches New Research Platform and Expands Access to High-Purity Laboratory Peptides
New York, New York--(Newsfile Corp. - May 1, 2026) - AminoQuest Labs® (https://aminoquestlabs.com), a U.S.-based supplier of research peptides, today announced the official launch of its new online pl...
Ryder Declares Quarterly Cash Dividend
MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder declares quarterly cash dividend.
Ryder announces new 2M share repurchase plan
Ryder (R) System announces its Board of Directors has authorized a new share repurchase plan. Under the new discretionary repurchase plan, Ryder management is authorized to repurchase up to 2M
Ryder Authorizes New Discretionary Plan to Repurchase Shares
MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder authorizes new discretionary plan to repurchase shares.
VVT Med Announces Positive Clinical Data for ScleroSafe(R) Published in Peer-Reviewed Indian Journal of Vascular and Endovascular Surgery
Prospective Study Conducted at Holy Spirit Hospital in Mumbai Reports 95% Vein Occlusion Rate at 30 Prospective Study Conducted at Holy Spirit Hospital in Mumbai Reports 95% Vein Occlusion Rate at 30
Envoy Medical Highlights First Clinical Data Presentations from Pivotal Clinical Study of Fully Implanted Acclaim(R) Cochlear Implant
Positive Initial 6-Month Data from First 10 Patients and Improvements in Speech Understanding and Quality of Life Scores Presented; Additional Presentations Scheduled in Early May Details to be Discus...
SphingoTec Introduces ELISA sphingotest(R) penKid(R) to Enable Broad Kidney Biomarker Testing for Research Applications
New ELISA sphingotest® penKid® enables widespread measurement of the kidney function biomarker Proenkephalin 119-159 (penKid) using standard laboratory equipment. Only available test to match SphingoT...
Ryder price target raised to $276 from $239 at Citi
Citi raised the firm’s price target on Ryder (R) to $276 from $239 and keeps a Buy rating on the shares.
Ryder price target raised to $250 from $203 at JPMorgan
JPMorgan analyst Brian Ossenbeck raised the firm’s price target on Ryder (R) to $250 from $203 and keeps a Neutral rating on the shares.
Ryder price target raised to $245 from $219 at Goldman Sachs
Goldman Sachs analyst Jordan Alliger raised the firm’s price target on Ryder (R) to $245 from $219 and keeps a Buy rating on the shares. Ryder reported stronger-than-expected operating EPS
Ryder price target raised to $253 from $202 at Baird
Baird analyst Daniel Moore raised the firm’s price target on Ryder (R) to $253 from $202 and keeps an Outperform rating on the shares. The firm updated its model following
Ryder price target raised to $250 from $220 at Barclays
Barclays raised the firm’s price target on Ryder (R) to $250 from $220 and keeps an Overweight rating on the shares. The company beat Q1 estimates and raised its full
Ryder System Earnings Call Transcript: Q1 2026
First-quarter results exceeded expectations with 3% EPS growth and strong used vehicle sales. Raised 2026 EPS guidance to $14.05-$14.80, supported by resilient contractual revenue and strategic initiatives. Free cash flow and ROE remain robust.
Ryder sees Q2 adjusted EPS $3.50-$3.75, consensus $3.58
06:57 EDT Ryder (R) sees Q2 adjusted EPS $3.50-$3.75, consensus $3.58
Ryder reports Q1 adjusted EPS $2.54, consensus $2.27
Reports Q1 revenue $3.13B, consensus $3.14B. “The Ryder (R) team delivered solid first quarter results that exceeded our expectations,” says Ryder Chief Executive Officer John Diez. “Outperformance wa...
Ryder Reports First Quarter 2026 Results
MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R) reported results for the three months ended March 31 as follows: Earnings Before Taxes Earnings Diluted Earnings Per Sha...
ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
SOLANA BEACH, CA / ACCESS Newswire / April 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brai...
Ryder Returns to ACT Expo 2026 to Spotlight Advanced Vehicle Technology Solutions & Industry Expertise
MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R) will return to the Advanced Clean Transportation (ACT) Expo, May 4–7 in Las Vegas, showcasing the company's industry expertise i...
Ryder Expands Alabama Footprint With New Truck Rental and Maintenance Facility in Huntsville
MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R) is expanding its Southeast presence with the opening of a new 10,000-square‑foot full-service commercial truck rental and maintenance facility in H...
Ryder Named to Fortune's “America's Most Innovative Companies” List for Second Consecutive Year
MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R) has been named to Fortune's “America's Most Innovative Companies” list for the second year in a row, underscoring the company's expanding role in a...
Ryder price target lowered to $239 from $245 at Citi
Citi lowered the firm’s price target on Ryder (R) to $239 from $245 and keeps a Buy rating on the shares.